ERT Virtual Visit keeps trials on track, patients at home

By Jenni Spinner

- Last updated on GMT

(cyano66/iStock via Getty Images Plus)
(cyano66/iStock via Getty Images Plus)

Related tags Clinical trials Decentralized trials Research COVID-19

The decentralized trial technology is intended to enable sites and sponsors to continue trials in the face of COVID-19 and other disruptive events.

ERT has launched Virtual Visit, a technology solution designed to enable clinical trial sites and sponsor to capture endpoint data without interruption, while minimizing risk to patients and staff. According to the company, the technology enables continuation of trials even in the face of current stay-at-home mandates and travel challenges.

With restrictions to both patients’ ability to travel and access to investigative sites, sponsors and CROs are tasked with discovering solutions that enable the interactions between site personnel and participants to continue. Studies frequently turn to telemedicine and other remote technologies.

Virtual Visit facilitates consultations between site personnel at their desks (either in the office or working from home) and patients in their homes or care facility. These consultations are conducted through a dedicated, secure app or web interface.

According to ERT, the Virtual Visit platform increases safety and convenience for the patients, while still empowering researchers to collect the safety and efficacy data necessary to support their development objectives.

Matthew McCarty, vice president at ERT, said the Virtual Visit technology enables researchers to overcome obstacles presented by situations like a pandemic.

We're pleased to offer another significant capability in a series of revolutionary virtual trial solutions to support our customers as they address the challenges presented by COVID-19​,” McCarty said. “Our research indicates that nearly 80% of the industry is shifting to virtual trial solutions during this unprecedented time and we remain committed to delivering the dynamic tools they need to continue their important, life-saving research​.”

According to ERT, the Virtual Visit solution enhances the patient experience by requiring fewer site trips, and less time spent at the site when such visits may be necessary. Additionally, the digital face-to-face meetings can help sustain patient engagement.

Additionally, Virtual Visit reportedly helps sites and sponsors via rapid deployment, ease of use, increased safety, and full compliance with regulatory requirements.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more